Erschienen in:
01.02.2013 | Original article
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR
verfasst von:
Carolina M. Soto, Jennifer D. Stone, Adam S. Chervin, Boris Engels, Hans Schreiber, Edward J. Roy, David M. Kranz
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 2/2013
Einloggen, um Zugang zu erhalten
Abstract
Clinical studies with immunotherapies for cancer, including adoptive cell transfers of T cells, have shown promising results. It is now widely believed that recruitment of CD4+ helper T cells to the tumor would be favorable, as CD4+ cells play a pivotal role in cytokine secretion as well as promoting the survival, proliferation, and effector functions of tumor-specific CD8+ cytotoxic T lymphocytes. Genetically engineered high-affinity T-cell receptors (TCRs) can be introduced into CD4+ helper T cells to redirect them to recognize MHC-class I-restricted antigens, but it is not clear what affinity of the TCR will be optimal in this approach. Here, we show that CD4+ T cells expressing a high-affinity TCR (nanomolar K
d value) against a class I tumor antigen mediated more effective tumor treatment than the wild-type affinity TCR (micromolar K
d value). High-affinity TCRs in CD4+ cells resulted in enhanced survival and long-term persistence of effector memory T cells in a melanoma tumor model. The results suggest that TCRs with nanomolar affinity could be advantageous for tumor targeting when expressed in CD4+ T cells.